Spotlight On... FDA pushes CTI to pull app for myelofibrosis med after trial deaths; Remicade biosim wins big FDA panel backing; Merck files dust mite allergy remedy in U.S.; and more...

The FDA has decided that the adverse events and deaths recorded in CTI BioPharma's pivotal program of the myelofibrosis drug pacritinib are so alarming that they've imposed a full clinical hold on the trial, halting dosing and persuading the biotech to yank its newly completed drug application. CTI is partnered with Baxalta ($BXLT) on the drug, which would compete with Novartis' ($NVS) Jakafi. More from FierceBiotech

> An FDA advisory panel overwhelmingly backed a biosimilar version of Johnson & Johnson's ($JNJ) Remicade, from Celltrion and Pfizer ($PFE), for all of the brand's approved indications. Report

> Merck & Co. ($MRK) filed for FDA approval for its dust mite allergy treatment. Report

> Novartis ($NVS) is taking aim at proposed changes to the U.K. Cancer Drugs Fund, which pays for treatments not cleared as cost-effective by government watchdogs. Report

And Finally... The National Institute for Health and Care Excellence (NICE) in England put out new guidelines for treatment multiple myeloma. Report

Suggested Articles

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

Provention Bio wants to connect the familial threads around Type 1 diabetes with two new campaigns—one targeted at doctors and the other at consumers.

Novartis’ latest campaign with a celebrity dance partner asks people to bust a move to raise awareness around sickle cell anemia and therapy Adakveo.